New triple therapy aims to shrink pancreatic tumors before surgery

NCT ID NCT07469956

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether giving a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and chemotherapy before surgery can help people with high-risk or borderline resectable pancreatic cancer. The study will enroll 30 participants and track how many are free of cancer events after 12 months. The goal is to see if this approach makes tumors easier to remove and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: surufatinib, toripalimab, and chemotherapy (mFOLFIRINOX)
What this could lead to: If this works, it could shrink pancreatic tumors enough to allow successful surgery, potentially improving long-term survival for patients with hard-to-treat pancreatic cancer.
What could go wrong: This is a small, early-phase trial with only 30 people, so results may not apply broadly. The combination of drugs can cause serious side effects, and it is not yet known if it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER RESECTABLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER RESECTABLE

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.